With one injection of ARISTADA INITIO and a single dose of oral aripiprazole plus ARISTADA 1064 mg, you can fully dose on day 1 for 2 months of treatment.1,2

IMPORTANT: Healthcare providers are responsible for keeping current and complying with all applicable coverage requirements and for the selection of diagnosis and procedure codes that accurately reflect their patient’s condition and the services rendered. Healthcare providers also are responsible for the accuracy of all claims and related documentation submitted for reimbursement. Additional insurance requirements may apply and healthcare providers should always contact the insurer directly to obtain complete and current information regarding coverage of ARISTADA and/or ARISTADA INITIO. Alkermes does not guarantee coverage or reimbursement. Under no circumstances will Alkermes, Inc., or its affiliates, employees, consultants, agents or representatives be liable for costs, expenses, losses, claims, liabilities or other damages that may arise from, or be incurred in connection with, the information provided here or any use thereof.

INDICATION
ARISTADA INITIO® (aripiprazole lauroxil), in combination with oral aripiprazole, is indicated for the initiation of ARISTADA® (aripiprazole lauroxil) when used for the treatment of schizophrenia in adults.

ARISTADA is indicated for the treatment of schizophrenia in adults.

IMPORTANT SAFETY INFORMATION FOR ARISTADA INITIO AND ARISTADA

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA INITIO and ARISTADA are not approved for the treatment of patients with dementia-related psychosis.

Contraindication: Known hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
The information in this summary is provided to help support coding and billing for patients with schizophrenia who are being treated with ARISTADA INITIO® (aripiprazole lauroxil) and/or ARISTADA® (aripiprazole lauroxil).

INDICATION
ARISTADA INITIO, in combination with oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults.
ARISTADA is indicated for the treatment of schizophrenia in adults.

INITIATION DOSING
ARISTADA INITIO is only to be used as a single dose to initiate ARISTADA treatment or as a single dose to re-initiate ARISTADA treatment following a missed dose of ARISTADA. ARISTADA INITIO is not for repeated dosing.

To initiate treatment with ARISTADA INITIO:

**DAY 1**

**STEP 1**
After establishing tolerability with oral aripiprazole, give patients a one-time ARISTADA INITIO injection and a single 30 mg dose of oral aripiprazole.

1 ARISTADA INITIO DOSE AND A SINGLE 30 MG DOSE OF ORAL ARIPIPRAZOLE

**STEP 2**
Select one ARISTADA dose and give on the same day or up to 10 days later if desired.

| 441 mg | 662 mg | 882 mg | 1064 mg |

**FIRST ARISTADA DOSE**

This is not all the information needed for dosing and administering ARISTADA INITIO and ARISTADA. Please consult the full Prescribing Information.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
CODING AND BILLING SUMMARY (CONTINUED)

NATIONAL DRUG CODES (NDCs)
The following NDC codes have been assigned to ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil). Coding decisions should be made by the physician based on an independent review of the patient’s condition.

<table>
<thead>
<tr>
<th>Dosage Strength</th>
<th>11-digit NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>675 mg</td>
<td>65757-0500-03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosage Strength</th>
<th>11-digit NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>441 mg</td>
<td>65757-0401-03</td>
</tr>
<tr>
<td>662 mg</td>
<td>65757-0402-03</td>
</tr>
<tr>
<td>882 mg</td>
<td>65757-0403-03</td>
</tr>
<tr>
<td>1064 mg</td>
<td>65757-0404-03</td>
</tr>
</tbody>
</table>

HEALTHCARE COMMON PROCEDURE CODING SYSTEM (HCPCS) CODES

**ARISTADA INITIO**
ARISTADA INITIO received its own J-code (J1943) effective for dates of service on and after October 1, 2019. The code J1943 may be used when ARISTADA INITIO is being billed under the medical benefit.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
<th>Settings of Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1943</td>
<td>Injection, aripiprazole lauroxil, (ARISTADA INITIO), 1 mg</td>
<td>Most payers and care settings</td>
</tr>
</tbody>
</table>

**ARISTADA**
ARISTADA received an updated J-Code (J1944) effective for dates of service on and after on October 1, 2019. The code J1944 may be used when ARISTADA is being billed under the medical benefit.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
<th>Settings of Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1944</td>
<td>Injection, aripiprazole lauroxil, (ARISTADA), 1 mg</td>
<td>Most payers and care settings</td>
</tr>
</tbody>
</table>

IMPORTANT SAFETY INFORMATION (CONTINUED)

**Cerebrovascular Adverse Reactions, Including Stroke:** Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, have been reported in placebo-controlled trials of elderly patients with dementia-related psychosis treated with risperidone, aripiprazole, and olanzapine. ARISTADA INITIO and ARISTADA are not approved for the treatment of patients with dementia-related psychosis.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
# SUMMARY INFORMATION FOR ARISTADA INITIO® (aripiprazole lauroxil)

<table>
<thead>
<tr>
<th>Code Set</th>
<th>Code³</th>
<th>Description</th>
<th>Settings of Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCPCS</td>
<td>J1943</td>
<td>Injection, aripiprazole lauroxil, (ARISTADA INITIO), 1 mg</td>
<td>Most payers and care settings</td>
</tr>
</tbody>
</table>

### Procedural Codes for ARISTADA INITIO⁶

| CPT**    | 96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular¹ |

---

# SUMMARY INFORMATION FOR ARISTADA® (aripiprazole lauroxil)

<table>
<thead>
<tr>
<th>Code Set</th>
<th>Code³</th>
<th>Description</th>
<th>Settings of Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCPCS</td>
<td>J1944</td>
<td>Injection, aripiprazole lauroxil, (ARISTADA), 1 mg</td>
<td>Most payers and care settings</td>
</tr>
</tbody>
</table>

### Procedural Codes for ARISTADA⁶

| CPT**    | 96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular¹ |

---

CMHC=Community Mental Health Center  
ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification  
DSM=American Psychiatric Association, Diagnostic and Statistical Manual  
* This code is not intended to be reported by the physician in the facility setting.  
¹ ARISTADA INITIO and ARISTADA are administered as IM injections only.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
SUMMARY INFORMATION FOR OUTPATIENT, PHYSICIAN OFFICE, OR CMHC SETTINGS (CONTINUED)

SHARED SUMMARY

Claims submitted for ARISTADA® (aripiprazole lauroxil) and/or ARISTADA INITIO® (aripiprazole lauroxil) should include at least one (1) ICD-10-CM diagnosis code to indicate the patient’s condition. Specific diagnosis codes should represent the condition as supported by the patient’s medical record. The diagnosis codes listed below may apply for patients for whom ARISTADA and/or ARISTADA INITIO may be appropriate.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F20.0</td>
<td>Paranoid schizophrenia</td>
</tr>
<tr>
<td>F20.1</td>
<td>Disorganized schizophrenia</td>
</tr>
<tr>
<td>F20.2</td>
<td>Catatonic schizophrenia</td>
</tr>
<tr>
<td>F20.3</td>
<td>Undifferentiated schizophrenia</td>
</tr>
<tr>
<td>F20.5</td>
<td>Residual schizophrenia</td>
</tr>
<tr>
<td>F20.89</td>
<td>Other schizophrenia</td>
</tr>
<tr>
<td>F20.9</td>
<td>Unspecified schizophrenia</td>
</tr>
</tbody>
</table>

IMPORTANT SAFETY INFORMATION (CONTINUED)

Potential for Dosing and Medication Errors: Medication errors, including substitution and dispensing errors, between ARISTADA INITIO and ARISTADA could occur. ARISTADA INITIO is intended for single administration in contrast to ARISTADA which is administered monthly, every 6 weeks, or every 8 weeks. Do not substitute ARISTADA INITIO for ARISTADA because of differing pharmacokinetic profiles.

Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex may occur with administration of antipsychotic drugs, including ARISTADA INITIO and ARISTADA. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal, involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing antipsychotics should be consistent with the need to minimize TD. Discontinue ARISTADA if clinically appropriate. TD may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include:

• Hyperglycemia/Diabetes Mellitus:
  Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. (CONTINUED)
CODING FOR TREATMENT WITH ARISTADA INITIO AND ARISTADA:
CLAIM FORM CMS-1500/837P (PHYSICIAN OFFICES AND CMHCs)

The 837P (Professional) is the standard format used by healthcare professionals and suppliers to transmit claims electronically. The CMS-1500 form is the standard paper claim form used to bill most insurance carriers, including Medicare, Medicaid, and commercial carriers when a paper claim is allowed. Data elements in the CMS uniform electronic billing specifications for 837P are consistent with the hard copy data set.6

Healthcare professionals and other qualified providers should submit all electronic claims using the 837P claims format, following ANSI ASC X12N 837P Version 5010A1 electronic data interchange transaction standards. Healthcare professionals in an office setting who treat Medicare beneficiaries may use the CMS-1500 form (02/12) for most payers who accept paper claims if a paper claim is necessary.7

The following information highlights some of the key product-specific fields in the 837P and the coordinating location on the CMS-1500 for Medicare claims reporting purposes. Please check with other payers for specific details and processes for use of appropriate forms.

RECORDING DRUG ADMINISTRATION

- The first ARISTADA® (aripiprazole lauroxil) injection may be administered on the same day as ARISTADA INITIO® (aripiprazole lauroxil) or up to 10 days thereafter
- Medication errors, including substitution and dispensing errors, between ARISTADA INITIO and ARISTADA could occur. ARISTADA INITIO is intended for single administration in contrast to ARISTADA which is administered monthly, every 6 weeks, or every 8 weeks. Do not substitute ARISTADA INITIO for ARISTADA because of differing pharmacokinetic profiles
- Subsequent ARISTADA doses may be administered on a monthly, 6 week, or 2 month dose intervals. Please see ARISTADA Prescribing Information for complete information regarding dosing and administration of ARISTADA
- Please see the following sample forms beginning on page 10 for examples based on the administration of the drug

IMPORTANT SAFETY INFORMATION (CONTINUED)

Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of antidiabetic treatment despite discontinuation of the suspect drug.

- Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
- Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
## Quick Reference Table for CMS-1500/837P

<table>
<thead>
<tr>
<th>Field/Category Name</th>
<th>ARISTADA INITIO* (aripiprazole lauroxil) Example*</th>
<th>ARISTADA* (aripiprazole lauroxil) Example*</th>
<th>837P Loop ID, Segment/Data Element*</th>
<th>CMS-1500 (02/12) Field Number*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedures, Services, or Supplies (e.g., NDCs)</td>
<td>675 mg: NDC 65757-0500-03</td>
<td>441 mg: NDC 65757-0401-03</td>
<td>Loop 2400/ SV101</td>
<td>Field 24D</td>
</tr>
<tr>
<td>Procedures, Services, or Supplies (e.g., CPT® code†)</td>
<td>96372 therapeutic, prophylactic, or diagnostic injection‡</td>
<td>96372 therapeutic, prophylactic, or diagnostic injection‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures, Services, or Supplies (e.g., HCPCS code)</td>
<td>J1943</td>
<td>J1944</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Units | 675 units for 675 mg | • 441 units for 441 mg  
• 662 units for 662 mg  
• 882 units for 882 mg  
• 1064 units for 1064 mg | Loop 2400/ SV104 | Field 24G |
| Diagnosis or Nature of Illness or Injury | Input appropriate diagnosis code | Input appropriate diagnosis code | Loop 2300/ HI01-2 to HI12-2 | Field 21 |


* All examples indicated should also include any placeholder digits required by the 837P format.

† This code is not intended to be reported by the physician in the facility setting.

‡ ARISTADA INITIO and ARISTADA are administered as IM injections only.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
HOSPITAL OUTPATIENT OR PARTIAL HOSPITALIZATION CODING FOR TREATMENT WITH ARISTADA INITIO AND ARISTADA:
CLAIM FORM UB-04/CMS-1450/837I

The 837I (Institutional) is the standard format used by institutional providers to transmit claims electronically.

The form UB-04, also known as the CMS-1450, is the standard claim form to bill Medicare Administrative Contractors (MACs) when a paper claim is allowed. Data elements in the CMS uniform electronic billing specifications for 837I are consistent with the hard copy data set.9

The 837I and UB-04 also may be suitable for billing various government and some commercial insurers. Please check with Medicaid programs and private payers for specific details and processes.

RECORDING DRUG ADMINISTRATION

• The first ARISTADA® (aripiprazole lauroxil) injection may be administered on the same day as ARISTADA INITIO® (aripiprazole lauroxil) or up to 10 days thereafter

• Medication errors, including substitution and dispensing errors, between ARISTADA INITIO and ARISTADA could occur. ARISTADA INITIO is intended for single administration in contrast to ARISTADA which is administered monthly, every 6 weeks, or every 8 weeks. Do not substitute ARISTADA INITIO for ARISTADA because of differing pharmacokinetic profiles

• Subsequent ARISTADA doses may be administered on a monthly, 6 week, or 2 month dose intervals. Please see ARISTADA Prescribing Information for complete information regarding dosing and administration of ARISTADA

• Please see the following sample forms beginning on page 10 for guidance based on the administration of the drug

IMPORTANT SAFETY INFORMATION (CONTINUED)

Pathological Gambling and Other Compulsive Behaviors: Compulsive or uncontrollable urges to gamble have been reported with use of aripiprazole. Other compulsive urges less frequently reported include sexual urges, shopping, binge eating and other impulsive or compulsive behaviors which may result in harm for the patient and others if not recognized. Closely monitor patients and consider dose reduction or stopping aripiprazole if a patient develops such urges.

Orthostatic Hypotension: Aripiprazole may cause orthostatic hypotension which can be associated with dizziness, lightheadedness, and tachycardia. Monitor heart rate and blood pressure, and warn patients with known cardiovascular or cerebrovascular disease and risk of dehydration and syncope.

Falls: Antipsychotics including ARISTADA INITIO and ARISTADA may cause somnolence, postural hypotension or motor and sensory instability which may lead to falls and subsequent injury. Upon initiating treatment and recurrently, complete fall risk assessments as appropriate.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue ARISTADA INITIO and/or ARISTADA at the first sign of a clinically significant decline in WBC and in severely neutropenic patients.

Seizures: Use with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
Quick Reference Table for UB-04/CMS-1450/837I

<table>
<thead>
<tr>
<th>Field/Category Name</th>
<th>ARISTADA INITIO® (aripiprazole lauroxil) Example</th>
<th>ARISTADA® (aripiprazole lauroxil) Example</th>
<th>837I Loop ID, Segment/Data Element</th>
<th>UB-04/CMS-1450®</th>
</tr>
</thead>
</table>
| **Revenue Code**    | • Medicare, revenue code 0636 (drugs that require detailed coding)  
                       • For non-Medicare payers, revenue code 0250 (general pharmacy)  
                       • Injection services may be reported with revenue code 0510 (clinic, general service)  
                       • **Medicare, revenue code 0636 (drugs that require detailed coding)**  
                       • For non-Medicare payers, revenue code 0250 (general pharmacy)  
                       • Injection services may be reported with revenue code 0510 (clinic, general service) | Loop 2400, SV201 | Field 42 |
| **Description**     | Medicare requirements for claims crossing over to Medicaid include the NDC qualifier N4 followed by the 11-digit NDC (e.g., N465757-0500-03)  
                       Medicare requirements for claims crossing over to Medicaid include the NDC qualifier N4 followed by the 11-digit NDC (e.g., N465757-XXXX-03) | Check with payer (instructions may vary) | Field 43 |
| **CPT® Code**†      | 96372 (therapeutic, prophylactic, or diagnostic injection)† | 96372 (therapeutic, prophylactic, or diagnostic injection)† | Loop 2400, SV202-2 | Field 44 |
| **HCPCS Code**      | J1943 for ARISTADA INITIO | J1944 for ARISTADA |  |  |
| **Service Units**   | 675 units for 675 mg  
                       • 441 units for 441 mg  
                       • 662 units for 662 mg  
                       • 882 units for 882 mg  
                       • 1064 units for 1064 mg | Loop 2400, SV205 | Field 46 |
| **Diagnosis**       | Input appropriate diagnosis code  
                       Input appropriate diagnosis code | Loop 2300, HI01-2 (HI01-1=BK) | Fields 67A-Q |


* This code is not intended to be reported by the physician in the facility setting.
† ARISTADA INITIO and ARISTADA are administered as IM injections only.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

**Potential for Cognitive and Motor Impairment:** ARISTADA INITIO and ARISTADA may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are certain therapy with ARISTADA INITIO and/or ARISTADA does not affect them adversely.

**Body Temperature Regulation:** Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Advise patients regarding appropriate care in avoiding overheating and dehydration. Appropriate care is advised for patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
ARISTADA INITIO AND ARISTADA SAME-DAY ADMINISTRATION

RECORDING DRUG ADMINISTRATION

• ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil) may be administered on the same day

• Following is an example of billing forms when drug administration happens on the same date. ARISTADA INITIO 675 mg and ARISTADA 662 mg are administered on October 1, 2019

SAMPLE CMS-1500 CLAIM FORM
(Physician Office Billing)

1. Enter 675 units for 675 mg ARISTADA INITIO
2. Ensure the correct dosage is listed for ARISTADA
   • 441 units for 441 mg
   • 662 units for 662 mg
   • 882 units for 882 mg
   • 1064 units for 1064 mg

This information is for example purposes and payer coding and billing requirements may vary. Please refer to payer guidance for specific claim form submission or specific coding use.


Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
COMPLETING THE CMS-1500 CLAIM FORM
ARISTADA INITIO SAME-DAY ADMINISTRATION

1. **DIAGNOSIS CODE (Field 21)**
Enter ICD-10-CM codes appropriate for the patient.

2. **PRIOR AUTHORIZATION NUMBER (Field 23)**
Document Prior Authorization number issued by the payer, if one is required.

3. **PRODUCT CODE (Field 24D)**
Document product use with HCPCS code, J1943 for ARISTADA INITIO® (aripiprazole lauroxil) and J1944 for ARISTADA® (aripiprazole lauroxil).

4. **DIAGNOSIS POINTER (Field 24E)**
Specify diagnosis, from Field 21, for each HCPCS/CPT® code listed.

5. **SERVICE UNITS (Field 24G)**
a. Report number of units of ARISTADA INITIO (one unit of J1943 is equal to 1 mg):
   - 675 units for 675 mg
b. Report number of units of ARISTADA (one unit of J1944 is equal to 1 mg):
   - 441 units for 441 mg
   - 662 units for 662 mg
   - 882 units for 882 mg
   - 1064 units for 1064 mg

   **Note:** Some payers may require a drug to be billed over two lines due to limitations in the amount of digits allowed in Field 24G. For example, when administering 1064 mg of ARISTADA, one line of J1944 would be represented as 999 service units and the second line of J1944 would be represented with 65 service units.

6. **PROCEDURE CODE (Field 24D)**
Document administration of ARISTADA INITIO and ARISTADA with CPT® code 96372 (therapeutic, prophylactic, or diagnostic injection [specify substance or drug], subcutaneous or intramuscular*) For some payers, the use of modifier 59 may be appropriate when performing 2 injections on the same visit.

*CPT®=Current Procedural Terminology. CPT® is a registered trademark of the American Medical Association.

* ARISTADA INITIO and ARISTADA are administered as IM injections only.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use; use caution in patients at risk for aspiration pneumonia.

**Concomitant Medication:** ARISTADA INITIO is only available at a single strength as a single-dose pre-filled syringe, so dosage adjustments are not possible. Avoid use in patients who are known CYP2D6 poor metabolizers or taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers, antihypertensive drugs or benzodiazepines.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
ARISTADA INITIO AND ARISTADA SAME-DAY ADMINISTRATION

RECORDING DRUG ADMINISTRATION

- ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil) may be administered on the same day
- Following is an example of billing forms when drug administration happens on the same date.

ARISTADA INITIO 675 mg and ARISTADA 662 mg are administered on October 1, 2019

SAMPLE CMS-1450 CLAIM FORM (HOSPITAL BILLING)

ARISTADA INITIO 675 mg AND ARISTADA 662 mg BOTH ADMINISTERED ON SAME DATE
(Shown here as October 1, 2019 for example purposes only)

This information is for example purposes and payer coding and billing requirements may vary. Please refer to payer guidance for specific claim form submission or specific coding use.


Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
COMPLETING THE CMS-1450 CLAIM FORM
ARISTADA INITIO SAME-DAY ADMINISTRATION

1. **REVENUE CODE (Field 42)**
   For unclassified drug codes revenue code 0636 (drugs that require detailed coding) may be appropriate due to additional information being reported in Box 80.

2. **DESCRIPTION (Field 43)**
   Include the NDC information for ARISTADA INITIO® (aripiprazole lauroxil) that includes the NDC qualifier N4 followed by the 11-digit NDC, unit of measure, and quantity delivered to the patient.

3. **HCPCS CODE (Field 44)**
   In Field 44, enter the applicable HCPCS or CPT® code (including any modifiers needed) to describe the drug and other separately billable services provided.
   - **HCPCS:** J1943 should be used for ARISTADA INITIO
   - J1944 should be used for ARISTADA® (aripiprazole lauroxil)
   - **HCPCS (CPT®) procedure example:** 96372 (therapeutic, prophylactic, or diagnostic injection [specify substance or drug], subcutaneous or intramuscular*)

4. **SERVICE UNITS (Field 46)**
   a. Report number of units of ARISTADA INITIO (one unit of J1943 is equal to 1 mg):
      - 675 units for 675 mg
   b. Report number of units of ARISTADA (one unit of J1944 is equal to 1 mg):
      - 441 units for 441 mg
      - 662 units for 662 mg
      - 882 units for 882 mg
      - 1064 units for 1064 mg

5. **DIAGNOSIS CODE (Field 67)**
   Enter the appropriate ICD-10 codes for the patient. This field should contain the ICD-10 diagnosis code that describes the primary reason that the patient is receiving the outpatient services described on the claim. Additional diagnosis codes should be included within Fields 67A-Q.

* ARISTADA INITIO and ARISTADA are administered as IM injections only.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**
Depending on the ARISTADA dose, adjustments may be recommended if patients are 1) known as CYP2D6 poor metabolizers and/or 2) taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers for greater than 2 weeks. Avoid use of ARISTADA 662 mg, 882 mg, or 1064 mg for patients taking both strong CYP3A4 inhibitors and strong CYP2D6 inhibitors. (See Table 4 in the ARISTADA full Prescribing Information.)

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
ARISTADA INITIO AND ARISTADA DIFFERENT DAY ADMINISTRATION

RECORDING DRUG ADMINISTRATION

- The first ARISTADA® (aripiprazole lauroxil) injection may be administered up to 10 days after ARISTADA INITIO® (aripiprazole lauroxil)
- Following is an example of billing forms when drug administration happens on different dates. ARISTADA INITIO 675 mg is administered on October 1, 2019 while ARISTADA 662 mg is administered on October 9, 2019

SAMPLE CMS-1500 CLAIM FORM (PHYSICIAN OFFICE BILLING)

Ensure the correct dosage is listed for ARISTADA
- 441 units for 441 mg
- 662 units for 662 mg
- 882 units for 882 mg
- 1064 units for 1064 mg

This information is for example purposes and payer coding and billing requirements may vary. Please refer to payer guidance for specific claim form submission or specific coding use.


Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
COMPLETING THE CMS-1500 CLAIM FORM
ARISTADA INITIO DIFFERENT DAY ADMINISTRATION

1. **DIAGNOSIS CODE (Field 21)**
   Enter ICD-10-CM codes appropriate for the patient.

2. **PRIOR AUTHORIZATION NUMBER (Field 23)**
   Document Prior Authorization number issued by the payer, if one is required.

3. **PRODUCT CODE (Field 24D)**
   Document product use with HCPCS code, J1943 for ARISTADA INITIO® (aripiprazole lauroxil) and J1944 for ARISTADA® (aripiprazole lauroxil).

4. **DIAGNOSIS POINTER (Field 24E)**
   Specify diagnosis, from Field 21, for each HCPCS/CPT® code listed.

5. **SERVICE UNITS (Field 24G)**
   a. Report number of units of ARISTADA INITIO (one unit of J1943 is equal to 1 mg):
      • 675 units for 675 mg
   b. Report number of units of ARISTADA (one unit of J1944 is equal to 1 mg):
      • 441 units for 441 mg   • 882 units for 882 mg
      • 662 units for 662 mg   • 1064 units for 1064 mg
   **Note:** Some payers may require a drug to be billed over two lines due to limitations in the amount of digits allowed in Field 24G. For example, bill one line of J1944 with 999 Service Units and bill a second line of J1944 with 65 Service Units.

6. **PROCEDURE CODE (Field 24D)**
   Document administration of ARISTADA INITIO and ARISTADA with CPT® code 96372 (therapeutic, prophylactic, or diagnostic injection [specify substance or drug], subcutaneous or intramuscular*). For some payers, the use of modifier 59 may be appropriate when performing 2 injections on the same visit.

* ARISTADA INITIO and ARISTADA are administered as IM injections only.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

**Commonly Observed Adverse Reactions:** In pharmacokinetic studies the safety profile of ARISTADA INITIO was generally consistent with that observed for ARISTADA. The most common adverse reaction (≥5% incidence and at least twice the rate of placebo reported by patients treated with ARISTADA 441 mg and 882 mg monthly) was akathisia.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
ARISTADA INITIO AND ARISTADA DIFFERENT DAY ADMINISTRATION

RECORDING DRUG ADMINISTRATION

- The first ARISTADA® (aripiprazole lauroxil) injection may be administered up to 10 days after ARISTADA INITIO® (aripiprazole lauroxil).
- Following is an example of billing forms when drug administration happens on different dates. ARISTADA INITIO 675 mg is administered on October 1, 2019 while ARISTADA 662 mg is administered on October 9, 2019.

SAMPLE CMS-1450 CLAIM FORM (HOSPITAL BILLING)

Ensure the correct dosage is listed for ARISTADA
- 441 units for 441 mg
- 662 units for 662 mg
- 882 units for 882 mg
- 1064 units for 1064 mg

This information is for example purposes and payer coding and billing requirements may vary. Please refer to payer guidance for specific claim form submission or specific coding use.


Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
COMPLETING THE CMS-1450 CLAIM FORM
ARISTADA INITIO DIFFERENT DAY ADMINISTRATION

1 REVENUE CODE (Field 42)
For unclassified drug codes revenue code 0636 (drugs that require detailed coding) may be appropriate due to additional information being reported in Box 80.

2 DESCRIPTION (Field 43)
Include the NDC information for ARISTADA INITIO® (aripiprazole lauroxil) that includes the NDC qualifier N4 followed by the 11-digit NDC, unit of measure and quantity delivered to the patient.

3 HCPCS CODE (Field 44)
In Field 44, enter the applicable HCPCS or CPT® code (including any modifiers needed) to describe the drug and other separately billable services provided.

HCPCS: J1943 should be used for ARISTADA INITIO
HCPCS (CPT®) procedure example: 96372 (therapeutic, prophylactic, or diagnostic injection [specify substance or drug], subcutaneous or intramuscular*)

4 SERVICE UNITS (Field 46)
a. Report number of units of ARISTADA INITIO (one unit of J1943 is equal to 1 mg):
   • 675 units for 675 mg

b. Report number of units of ARISTADA® (aripiprazole lauroxil) (one unit of J1944 is equal to 1 mg):
   • 441 units for 441 mg
   • 662 units for 662 mg
   • 882 units for 882 mg
   • 1064 units for 1064 mg

5 DIAGNOSIS CODE (Field 67)
Enter the appropriate ICD-10 codes for the patient. This field should contain the ICD-10 diagnosis code that describes the primary reason that the patient is receiving the outpatient services described on the claim. Additional diagnosis codes should be included within Fields 67A-Q.

* ARISTADA INITIO and ARISTADA are administered as IM injections only.

IMPORTANT SAFETY INFORMATION (CONTINUED)
Injection-Site Reactions: In pharmacokinetic studies evaluating ARISTADA INITIO, the incidences of injection-site reactions with ARISTADA INITIO were similar to the incidence observed with ARISTADA. Injection-site reactions were reported by 4%, 5%, and 2% of patients treated with 441 mg ARISTADA (monthly), 882 mg ARISTADA (monthly), and placebo, respectively. Most of these were injection-site pain and associated with the first injection and decreased with each subsequent injection. Other injection-site reactions (induration, swelling, and redness) occurred at less than 1%.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
Please verify with the payer any character/digit limitations, e.g., 3-digit limitation in Field 24G (Days or Units) when billing for the 1064 mg dose of ARISTADA® (aripiprazole lauroxil).

For payers that do not allow 4-digit billing in Field 24G, please see the method below for billing the 1064 mg dose.

Field 24G
Some payers may not allow 4 digits in Field 24G. Please confirm billing guidelines with the payer.
Note: See sample below for split-line billing if payer cannot accept 4 digits in Field 24G

When billing 1064 units and payer only accepts up to 3 digits, split the units over 2 lines:
999 + 65 = 1064 units

ARISTADA 1064 mg
ADMINISTERED ON OCTOBER 1, 2019
(Shown here as October 1, 2019 for example purposes only)

This information is for example purposes and payer coding and billing requirements may vary. Please refer to payer guidance for specific claim form submission or specific coding use.

* In conjunction with 21 consecutive days of oral aripiprazole supplementation.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy/Nursing: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider of a known or suspected pregnancy. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA INITIO and/or ARISTADA during pregnancy. Aripiprazole is present in human breast milk. The benefits of breastfeeding should be considered along with the mother’s clinical need for ARISTADA INITIO and/or ARISTADA and any potential adverse effects on the infant from ARISTADA INITIO and/or ARISTADA or from the underlying maternal condition.

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
Please verify with the payer any character/digit limitations, e.g., 3-digit limitation in Field 46 (Service Units) when billing for the 1064 mg dose of ARISTADA® (aripiprazole lauroxil).

For payers that do not allow 4-digit billing in Field 46, please see the method below for billing the 1064 mg dose.

When billing 1064 units and payer requires 3 digits, split the units over 2 lines: 999+65 = 1064 units.
COMPLETING THE CMS-1450 CLAIM FORM
ARISTADA-ONLY ADMINISTRATION

1. **REVENUE CODE (Field 42)**
   Enter the appropriate revenue code(s).

   **Revenue code examples:**
   - For Medicare, revenue code 0636 (drugs that require detailed coding) may be appropriate
   - For Non-Medicare payers, revenue code 0250 (general pharmacy) may be appropriate
   - Injection services may be reported with revenue code 0510 (clinic, general service)

2. **DESCRIPTION (Field 43)**
   This field is not required. However, for Medicare claims where Medicaid is the secondary payer, Field 43 should be used to report drug rebate information for Medicaid crossover purposes.

   The format required by Medicare includes the NDC qualifier N4 followed by the 11-digit NDC in positions 01-13 (e.g., N465757-XXXX-03 minus any dashes). Report the NDC quantity qualifier followed by the quantity beginning in position 14. The Description Field on Form CMS-1450 is 24 characters long.

3. **HCPCS CODE (Field 44)**
   In Field 44, enter the applicable HCPCS or CPT® code (including any modifiers needed) to describe the drug and other separately billable services provided.

   **HCPCS:** J1944 should be used for ARISTADA® (aripiprazole lauroxil)

   **HCPCS (CPT®) procedure example:** 96372 (therapeutic, prophylactic, or diagnostic injection [specify substance or drug], subcutaneous or intramuscular*)

4. **SERVICE UNITS (Field 46)**
   Report number of units of ARISTADA (one unit of J1944 is equal to 1 mg):
   - 441 units for 441 mg
   - 882 units for 882 mg
   - 662 units for 662 mg
   - 1064 units for 1064 mg

5. **DIAGNOSIS CODE (Field 67)**
   Enter the appropriate ICD-10 codes for the patient. This field should contain the ICD-10 diagnosis code that describes the primary reason that the patient is receiving the outpatient services described on the claim. Additional diagnosis codes should be included within Fields 67A-Q.

---


* ARISTADA is administered as an IM injection only.
IMPORTANT SAFETY INFORMATION FOR ARISTADA INITIO AND ARISTADA

INDICATION and IMPORTANT SAFETY INFORMATION for ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use

INDICATION
ARISTADA INITIO, in combination with oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults. ARISTADA is indicated for the treatment of schizophrenia in adults.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA INITIO and ARISTADA are not approved for the treatment of patients with dementia-related psychosis.

Contraindication: Known hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis.

Cerebrovascular Adverse Reactions, Including Stroke:
Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, have been reported in placebo-controlled trials of elderly patients with dementia-related psychosis treated with risperidone, aripiprazole, and olanzapine. ARISTADA INITIO and ARISTADA are not approved for the treatment of patients with dementia-related psychosis.

Potential for Dosing and Medication Errors: Medication errors, including substitution and dispensing errors, between ARISTADA INITIO and ARISTADA could occur. ARISTADA INITIO is intended for single administration in contrast to ARISTADA which is administered monthly, every 6 weeks, or every 8 weeks. Do not substitute ARISTADA INITIO for ARISTADA because of differing pharmacokinetic profiles.

Neuroleptic Malignant Syndrome (NMS):
A potentially fatal symptom complex may occur with administration of antipsychotic drugs, including ARISTADA INITIO and ARISTADA. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD):
The risk of developing TD (a syndrome of abnormal, involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing antipsychotics should be consistent with the need to minimize TD. Discontinue ARISTADA if clinically appropriate. TD may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include:

- Hyperglycemia/Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of antidiabetic treatment despite discontinuation of the suspect drug.

- Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

- Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Pathological Gambling and Other Compulsive Behaviors:
Compulsive or uncontrollable urges to gamble have been reported with use of aripiprazole. Other compulsive urges less frequently reported include sexual urges, shopping, binge eating and other impulsive or compulsive behaviors which may result in harm for the patient and others if not recognized. Closely monitor patients and consider dose reduction or stopping aripiprazole if a patient develops such urges.

Please see accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.
ORTHOSTATIC HYPOTENSION: Aripiprazole may cause orthostatic hypotension which can be associated with dizziness, lightheadedness, and tachycardia. Monitor heart rate and blood pressure, and warn patients with known cardiovascular or cerebrovascular disease and risk of dehydration and syncpe.

Falls: Antipsychotics including ARISTADA INITIO and ARISTADA may cause somnolence, postural hypotension or motor and sensory instability which may lead to falls and subsequent injury. Upon initiating treatment and recurrently, complete fall risk assessments as appropriate.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue ARISTADA INITIO and/or ARISTADA at the first sign of a clinically significant decline in WBC and in severely neutropenic patients.

Seizures: Use with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Potential for Cognitive and Motor Impairment: ARISTADA INITIO and ARISTADA may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are certain therapy with ARISTADA INITIO and/or ARISTADA does not affect them adversely.

Body Temperature Regulation: Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Advise patients regarding appropriate care in avoiding overheating and dehydration. Appropriate care is advised for patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use; use caution in patients at risk for aspiration pneumonia.

Concomitant Medication: ARISTADA INITIO is only available at a single strength as a single-dose pre-filled syringe, so dosage adjustments are not possible. Avoid use in patients who are known CYP2D6 poor metabolizers or taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers, antihypertensive drugs or benzodiazepines.

Depending on the ARISTADA dose, adjustments may be recommended if patients are 1) known as CYP2D6 poor metabolizers and/or 2) taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers for greater than 2 weeks. Avoid use of ARISTADA 662 mg, 882 mg, or 1064 mg for patients taking both strong CYP3A4 inhibitors and strong CYP2D6 inhibitors. (See Table 4 in the ARISTADA full Prescribing Information.)

Commonly Observed Adverse Reactions: In pharmacokinetic studies the safety profile of ARISTADA INITIO was generally consistent with that observed for ARISTADA. The most common adverse reaction (≥5% incidence and at least twice the rate of placebo reported by patients treated with ARISTADA 441 mg and 882 mg monthly) was akathisia.

Injection-Site Reactions: In pharmacokinetic studies evaluating ARISTADA INITIO, the incidences of injection-site reactions with ARISTADA INITIO were similar to the incidence observed with ARISTADA. Injection-site reactions were reported by 4%, 5%, and 2% of patients treated with 441 mg ARISTADA (monthly), 882 mg ARISTADA (monthly), and placebo, respectively. Most of these were injection-site pain and associated with the first injection and decreased with each subsequent injection. Other injection-site reactions (induration, swelling, and redness) occurred at less than 1%.

Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy/Nursing: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider of a known or suspected pregnancy. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA INITIO and/or ARISTADA during pregnancy. Aripiprazole is present in human breast milk. The benefits of breastfeeding should be considered along with the mother’s clinical need for ARISTADA INITIO and/or ARISTADA and any potential adverse effects on the infant from ARISTADA INITIO and/or ARISTADA or from the underlying maternal condition.

ARISTADA Care Support provides a comprehensive suite of services to help make ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil) therapy more accessible for patients.

**ACCESS SERVICES**

Reimbursement support and financial assistance programs to help patients access treatment.

**HOSPITAL SERVICES**

A program to help hospitalized patients trial ARISTADA INITIO and ARISTADA in the hospital.

A program to help patients secure potential sites and providers for follow-up care.

**PRODUCT SUPPORT**

Samples, ordering information, and answers to questions about ARISTADA INITIO and ARISTADA.

**PATIENT SUPPORT**

Educational materials, transition assistance, injection provider locator, and appointment reminders are available for patients and caregivers who need them.

Learn more at ARISTADACareSupport.com, or call us at 1-866-ARISTADA (1-866-274-7823) Monday through Friday, 9 AM to 8 PM EST

Please see additional Important Safety Information on pages 22-23 and accompanying full Prescribing Information, including Boxed Warning, for ARISTADA INITIO and ARISTADA.